Data Monitoring Committee (DMC) has performed another, scheduled review of the CHF trial data and recommended continuation of the trial without modification. Enrollment of this Phase 3 trial is expected to be completed by the end of 2018.
LVAD National Institutes for Health (NIH) Phase 2 trial has also completed enrollment with 12-month data read-out expected in the next quarter (Q3 CY18). Mesoblast is actively pursuing a potential accelerated entry pathway for MPC-150-IM into the cardiovascular market that may be provided by RMAT designation.
So, my take on this is both of these Tier 1 trials are confirmed on track with results coming in expected time-frames.
Data Monitoring Committee (DMC) has performed another, scheduled...
-
- There are more pages in this discussion • 115 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $1.381B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $5.683M | 4.776M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 19746 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |